Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Increasing Incidence of Prostate Cancer: A Matter of Early Detection?

No. 01 | 11/01/2005 | by (Koh)

Over the past five decades, the number of men diagnosed with prostate cancer in Western industrialized nations has been rising – and the cancer is diagnosed at ever younger ages of the patients.This increase is at least partly due to early detection screenings that have been introduced, as is shown by a study of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).

Based on data contained in the Swedish Family Cancer Register, epidemiologists Professor Dr. Kari Hemminki, Rajesh Rawal and Dr. Justo Lorenzo Bermejo have calculated that the number of prostate cancer cases in Sweden has almost tripled between 1960 and 2002. The increase occurred in two distinct phases: Up until 1995, primarily the incidence among elderly men after age 70 was on the rise. The steep upward flux of the incidence curve observed after 1995 concerns mainly younger men in their sixties. During the first phase until 1995, early detection of prostate cancer was usually based on tissue biopsies.The second phase of the rise started parallel to the introduction of tests for prostate-specific antigen (PSA tests). This suggests that younger men, too, have undergone this simple blood test even before symptoms of cancer start occurring. The fact that carcinomas in very early stages are thereby detected could at least partly account for the rise. Thus, similar increases were observed in the incidences of breast cancer following the introduction of mammography screenings and of cervical cancer after PAP smears for early diagnosis had been introduced.

Participation in early detection screenings also has effects on familial cancer risk. Hemminki and Lorenzo Bermejo have analyzed data of brother pairs who were both affected by prostate cancer. If one of the brothers is diagnosed with the disease, then there are increased chances that the other one, concerned about his own health, will undergo an early detection examination. This may reveal carcinomas which have not yet produced any symptoms and which, under different familial circumstances, may not have been detected until many years later or possibly never at all.

Due to this effect, the scientists advise to also apply caution when analyzing data on genetic cancer risk: Human behavior is influenced by many factors that may have an effect on cancer statistics and may at first sight be misinterpreted as genetic influences.

* Kari Hemminki, Rajesh Rawal and Justo Lorenzo Bermejo: Prostate Cancer Screening, Changing Age-specific Incidence Trends and Implications on Familial Risk. International Journal of Cancer 113, 312; 2005

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS